Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Özgüroğlu M, et al. Among authors: gullo g. Lancet Oncol. 2023 Sep;24(9):989-1001. doi: 10.1016/S1470-2045(23)00329-7. Epub 2023 Aug 14. Lancet Oncol. 2023. PMID: 37591293 Clinical Trial.
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Gümüş M, Chen CI, Ivanescu C, Kilickap S, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Harnett J, Mastey V, Naumann U, Reaney M, Konidaris G, Sasane M, Brady KJS, Li S, Gullo G, Rietschel P, Sezer A. Gümüş M, et al. Among authors: gullo g. Cancer. 2023 Jan 1;129(1):118-129. doi: 10.1002/cncr.34477. Epub 2022 Oct 29. Cancer. 2023. PMID: 36308296 Free PMC article. Clinical Trial.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Makharadze T, et al. Among authors: gullo g. J Thorac Oncol. 2023 Jun;18(6):755-768. doi: 10.1016/j.jtho.2023.03.008. Epub 2023 Mar 29. J Thorac Oncol. 2023. PMID: 37001859 Free article. Clinical Trial.
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.
Feliciano JL, McLoone D, Xu Y, Quek RGW, Kuznik A, Pouliot JF, Gullo G, Rietschel P, Guyot P, Konidaris G, Chan K, Keeping S, Wilson FR, Freemantle N. Feliciano JL, et al. Among authors: gullo g. Front Oncol. 2023 Apr 4;12:1081729. doi: 10.3389/fonc.2022.1081729. eCollection 2022. Front Oncol. 2023. PMID: 37082098 Free PMC article.
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Makharadze T, Quek RGW, Melkadze T, Gogishvili M, Ivanescu C, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Konidaris G, Rietschel P, Gullo G. Makharadze T, et al. Among authors: gullo g. Cancer. 2023 Jul 15;129(14):2256-2265. doi: 10.1002/cncr.34687. Epub 2023 May 8. Cancer. 2023. PMID: 37151113 Clinical Trial.
Response to Letter to the Editor.
Makharadze T, Gogishvili M, Baramidze A, Li S, Li Y, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Makharadze T, et al. Among authors: gullo g. J Thorac Oncol. 2023 Jul;18(7):e74-e75. doi: 10.1016/j.jtho.2023.05.012. J Thorac Oncol. 2023. PMID: 37348997 No abstract available.
Current Preoperative Management of Vulvar Squamous Cell Carcinoma: An Overview.
Della Corte L, Cafasso V, Guarino MC, Gullo G, Cucinella G, Lopez A, Zaami S, Riemma G, Giampaolino P, Bifulco G. Della Corte L, et al. Among authors: gullo g. Cancers (Basel). 2024 May 11;16(10):1846. doi: 10.3390/cancers16101846. Cancers (Basel). 2024. PMID: 38791925 Free PMC article. Review.
149 results